# Understanding and targeting RNA/transcription-dependent DNA repair in cancer cells

> **NIH NIH R50** · MASSACHUSETTS GENERAL HOSPITAL · 2022 · $84,389

## Abstract

Project Summary/Abstract
 Genomic instability is a hallmark of cancer and is an enabling characteristic of tumorigenesis. Genomic
instability can arise from deficiency in DNA repair system. On one hand, deficiency in DNA repair system leads
to increased mutation rate in the entire genome, results in genomic instability. On the other hand, deficiency in
certain DNA repair pathway(s) may render the cell highly dependent on other repair pathway(s) to cope with high
mutation burden, which may constitute a vulnerability that can be exploited for targeted therapies in cancer.
Recent success of the PARP inhibitors for treatment of BRCA mutation cancers, has demonstrated great
potential to exploit cancer cell-specific dependency on certain DNA repair pathways for cancer therapies. In
addition to cancer with BRCA deficiency, multiple researches have suggested to expand PARP inhibitor
treatment to cancers with deficiency in homologous recombination (HR) DNA repair pathways. However, our
understanding of the HR DNA repair pathways is quite limited. In our recent study on HR DNA repair, we have
discovered a novel RNA-dependent HR DNA repair pathway, which is controlled by the DNA repair protein
RAD51AP1. The unique ability of RAD51AP1 to promote HR in transcribed regions makes it an attractive target
to specifically exacerbate the DNA damage in active genes in cancer cells, especially in cancers driven by
oncogenic transcription factors or epigenetic regulators. The amplification and up-regulation of RAD51AP1 in
multiple types of cancer have led us to hypothesize that RAD51AP1 may be indispensable in cancer cells with
high levels of transcription-driven DNA damage and defects in the canonical HR pathway, which could be
exploited for therapeutic interventions. Importantly, the function of RAD51AP1 in promoting HR repair depends
on its R-loop formation activity via its DNA/RNA binding motif. This binding interface could potentially provide a
targetable site for small molecules to disrupt RAD51AP1 binding to DNA/RNA, which may effectively abolish its
R-loop formation activity and results in attenuating its HR DNA repair function in the cell.
 In summary, we want to expand our mechanistic understanding of the novel RNA/transcription-dependent
HR DNA repair pathway, investigate the role of this novel DNA repair in specific types of cancer, ultimately,
exploit cancer cell-specific dependency of this pathway for potential cancer therapies.

## Key facts

- **NIH application ID:** 10516451
- **Project number:** 1R50CA274158-01
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Jian Ouyang
- **Activity code:** R50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $84,389
- **Award type:** 1
- **Project period:** 2022-09-01 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10516451

## Citation

> US National Institutes of Health, RePORTER application 10516451, Understanding and targeting RNA/transcription-dependent DNA repair in cancer cells (1R50CA274158-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10516451. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*